Scarica l'app Stockscreener
31.49
1.29%
0.4197
Agios Pharmaceuticals Inc Borsa (AGIO) Ultime notizie
Agios Pharmaceuticals at Barclays Conference: Strategic Advances in Rare Disease Treatments - Investing.com UK
Q1 EPS Estimate for Agios Pharmaceuticals Lowered by Analyst - Defense World
FY2027 Earnings Estimate for AGIO Issued By Zacks Research - Defense World
Agios Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Agios Pharmaceuticals Announces Inducement Equity Awards for New Executive - GuruFocus.com
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer - The Manila Times
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate - EIN News
Celldex Therapeutics and Agios Pharmaceuticals to Present at March 2025 Investor Conferences - Barchart
Meet Agios' New Strategy Chief: Inside the $2M+ Executive Compensation Deal - StockTitan
Agios Pharmaceuticals chief commercial officer sells $59,742 in stock By Investing.com - Investing.com South Africa
Agios Pharmaceuticals chief commercial officer sells $59,742 in stock - Investing.com India
Agios Pharmaceuticals CEO sells shares worth $460,135 - Investing.com
Agios to Present at Upcoming Investor Conferences - The Manila Times
Where to Hear Agios Management Next Month: Key Investor Conferences Revealed - StockTitan
Insmed, Agios rise; DraftKings, Atlantica fall, Tuesday, 5/28/2024 - Star Tribune
Is Agios Pharmaceuticals, Inc. (AGIO) the Best Small-Cap Stock to Buy Now? - Insider Monkey
Y Intercept Hong Kong Ltd Acquires Shares of 45,817 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
What is HC Wainwright's Estimate for AGIO Q1 Earnings? - MarketBeat
Earnings call transcript: Agios Pharm Q4 2024 beats EPS forecast, stock rises - MSN
10 Best Small-Cap Stocks to Buy Now - Insider Monkey
Gilbert Cisneros conducts multiple transactions in stocks including Agios Pharmaceuticals and Airbnb - MSN
Sickle Cell Disease Market Growth Projections 2024-2034: - openPR
Q4 Earnings Estimate for AGIO Issued By HC Wainwright - MarketBeat
Venturi Wealth Management LLC Takes Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
What is HC Wainwright’s Estimate for AGIO Q4 Earnings? - Defense World
Agios Bolsters Coffers With $1.1 Bln Milestone Payments Following FDA Approval Of Vorasidenib - RTTNews
H.C. Wainwright sets $58 target on Agios Pharma stock with Buy rating By Investing.com - Investing.com South Africa
H.C. Wainwright starts Agios Pharmaceuticals coverage with 'buy' - TradingView
H.C. Wainwright sets $58 target on Agios Pharma stock with Buy rating - Investing.com India
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Down 6.0% in January - MarketBeat
Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025 - The Manila Times
Why Agios Pharmaceuticals' (NASDAQ:AGIO) Earnings Are Weaker Than They Seem - Simply Wall St
Rare Disease Leader Agios Takes Center Stage at Major Healthcare ConferenceKey Details Inside - StockTitan
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q4 2024 Earnings Call Transcript - MSN
Agios Pharmaceuticals (NASDAQ:AGIO) Downgraded by StockNews.com to "Sell" - MarketBeat
Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues - MSN
Agios Pharmaceuticals (NASDAQ: AGIO) Board Member Resignation: David P. Schenkein Steps Down - Defense World
Here's Why Agios Stock Plummeted More Than 20% on Monday - MSN
Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates - MSN
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates - MSN
Agios Pharmaceuticals price target lowered to $74 from $75 at Scotiabank - Yahoo Finance
Agios Pharmaceuticals announces board resignation - MSN
Long Term Trading Analysis for (AGIO) - Stock Traders Daily
Agios Pharmaceuticals: Liver Toxicity Issues May Threaten Thalassemia Approval (Rating Downgrade) - Seeking Alpha
Positive Phase III ACTIVATE-Kids study of Agios’ mitapivat - The Pharma Letter
Agios Pharmaceuticals Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Agios Pharmaceuticals Inc (AGIO) Q4 2024 Earnings Call Highlight - GuruFocus.com
Agios Pharmaceuticals Inc (AGIO) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ... - Yahoo Finance
0.70%
0.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):